Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

FOXBOROUGH, MA. — As the New England Patriots place the finishing touches on their game plan for a Week 17 showdown against the New York Jets at MetLife Stadium, they may have the services of a highly ...

Macworld reports that Apple’s iPhone 18 Pro may feature the first-ever redesign of the Dynamic Island, making it significantly smaller than current models. The redesign could utilize micro-transparent ...

International Business Machines stock is getting slammed Monday, becoming the latest perceived victim of rapidly developing AI technology, after Anthropic said its Claude Code tool could be used to ...

Across industries, pricing strategies are quietly shifting. What was once a predictable rhythm of annual increases is now giving way to continuous, incremental adjustments—and, in some cases, fully ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

If you feel like you’re being nickel-and-dimed everywhere you shop – you probably are. Instacart has been using a shady AI algorithm that charges different prices to different customers on the same ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...